US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MBX Biosciences

11.37

-0.4900-4.13%

Post-market: 11.370.00000.00%16:04 EDT

Volume:170.59K

Turnover:1.99M

Market Cap:380.04M

PE:-2.89

High:12.46

Open:11.88

Low:11.30

Close:11.86

Loading ...

Overview Company News Filings

MBX Biosciences Inc. Concluded Annual Stockholders Meeting

MBX Biosciences to Participate in June Investor Conferences

Buy Rating for Microbix Biosystems: Strong Antigen Revenue Growth and Mid-Term Market Potential

MBX Biosciences Reports Q1 2025 Financial Progress

MBX Biosciences Q1 EPS $(0.71) Beats $(0.77) Estimate

Press Release: MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Microbix Biosystems to Release Q2 Fiscal 2025 Results

Microbix Advances Kinlytic Urokinase Production with New CDMO Agreement

Kaia Network Users Reach Record High, as KLEVA Soars 119% | Top Altcoins to Watch Today

My Foodie Box Explores New Ventures Post-Divestment

Director Makes Bold Move with Major MBX Biosciences Stock Purchase

Strategic Positioning and Market Dynamics Justify Buy Rating for Microbix Biosystems

Microbix Biosystems Navigates Tariff Challenges with Strategic Growth

Press Release: MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

MBX Biosciences, Inc.: Promising Outlook with Strong Financials and Key Catalysts

MBX Biosciences Q4 2024 GAAP EPS $(0.47) Beats $(0.59) Estimate, $262.1M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2024; Expected To Support Operations Into Mid-2027

Mbx Biosciences Inc: Qtrly Loss per Share $0.47

THOMSON REUTERS

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Microbix Partners with ACPCC to Combat Cervical Cancer in Indo-Pacific

Insider Buyers At MBX Biosciences Likely Disappointed With 17% Slide

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MBX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","market":"US","secType":"STK","nameCN":"MBX Biosciences","latestPrice":11.37,"timestamp":1749240000000,"preClose":11.86,"halted":0,"volume":170592,"hourTrading":{"tag":"盘后","latestPrice":11.37,"preClose":11.37,"latestTime":"16:04 EDT","volume":2,"amount":22.74,"timestamp":1749240244183},"delay":0,"floatShares":13610296,"shares":33424371,"eps":-3.929565,"marketStatus":"Market Closed","change":-0.49,"latestTime":"06-06 16:00:00 EDT","open":11.88,"high":12.46,"low":11.3,"amount":1993082.7918,"amplitude":0.097808,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.929565,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":11.86,"preHourTrading":{"tag":"盘前","latestPrice":11.81,"preClose":11.86,"latestTime":"08:21 EDT","volume":504,"amount":5952.240000000001,"timestamp":1749212515100},"postHourTrading":{"tag":"盘后","latestPrice":11.37,"preClose":11.37,"latestTime":"16:04 EDT","volume":2,"amount":22.74,"timestamp":1749240244183},"volumeRatio":0.7295438043763247,"impliedVol":2.0644,"impliedVolPercentile":0.7561},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","floatShares":13610296,"roa":"-31.68%","roe":"-48.22%","lyrEps":-5.818121,"volumeRatio":0.7295438043763247,"shares":33424371,"dividePrice":0,"high":12.46,"amplitude":0.097808,"preClose":11.86,"low":11.3,"week52Low":4.8069,"pbRate":"1.61","week52High":27.5,"institutionHeld":0,"latestPrice":11.37,"eps":-3.929565,"divideRate":0,"volume":170592,"delay":0,"ttmEps":-3.929565,"open":11.88,"prevYearClose":18.43,"prevWeekClose":12.42,"prevMonthClose":12.42,"prevQuarterClose":7.38,"fiveDayClose":12.42,"twentyDayClose":11.71,"sixtyDayClose":9.39},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MBX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541852464","title":"MBX Biosciences Inc. Concluded Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541852464","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541852464?lang=en_us&edition=fundamental","pubTime":"2025-06-06 20:00","pubTimestamp":1749211210,"startTime":"0","endTime":"0","summary":"MBX Biosciences Inc. held its annual meeting of stockholders on June 5, 2025. During the meeting, stockholders voted on two proposals. The election of Tiba Aynechi, Ph.D. and P. Kent Hawryluk to the Board of Directors was approved. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL5dhBY8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2536617915","title":"MBX Biosciences to Participate in June Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2536617915","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536617915?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:00","pubTimestamp":1747742400,"startTime":"0","endTime":"0","summary":"CARMEL, Ind., May  20, 2025  (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/05/20/3084801/0/en/MBX-Biosciences-to-Participate-in-June-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4092","HP","PBH","MBX","BK4007"],"gpt_icon":0},{"id":"2536792635","title":"Buy Rating for Microbix Biosystems: Strong Antigen Revenue Growth and Mid-Term Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2536792635","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536792635?lang=en_us&edition=fundamental","pubTime":"2025-05-19 23:25","pubTimestamp":1747668310,"startTime":"0","endTime":"0","summary":"Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Microbix Biosystms (MBX – Research Report), with a price target of C$0.80. Davi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-microbix-biosystems-strong-antigen-revenue-growth-and-mid-term-market-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-microbix-biosystems-strong-antigen-revenue-growth-and-mid-term-market-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2535064747","title":"MBX Biosciences Reports Q1 2025 Financial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2535064747","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535064747?lang=en_us&edition=fundamental","pubTime":"2025-05-14 12:40","pubTimestamp":1747197656,"startTime":"0","endTime":"0","summary":"MBX Biosciences, Inc. ( ($MBX) ) has released its Q1 earnings. Here is a breakdown of the information MBX Biosciences, Inc. presented to its invest...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-reports-q1-2025-financial-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-reports-q1-2025-financial-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","MBX","PRGS","BK4007","LU2065732104.USD"],"gpt_icon":0},{"id":"2534275352","title":"MBX Biosciences Q1 EPS $(0.71) Beats $(0.77) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2534275352","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534275352?lang=en_us&edition=fundamental","pubTime":"2025-05-12 21:32","pubTimestamp":1747056738,"startTime":"0","endTime":"0","summary":"MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.77) by 7.79 percent. This is a 93.08 percent increase over losses of $(10.26) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45347389/mbx-biosciences-q1-eps-0-71-beats-0-77-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"gpt_icon":0},{"id":"2534224554","title":"Press Release: MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2534224554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534224554?lang=en_us&edition=fundamental","pubTime":"2025-05-12 20:00","pubTimestamp":1747051200,"startTime":"0","endTime":"0","summary":"Topline results for the Phase 2 Avail evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025. Investigational New Drug submission for MBX 4291 on track for 2Q 2025. $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027. \"We've followed up on our strong execution in 2024 with excellent progress on all our programs enabled by a strong balance sheet and cash position,\" said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. \"Following full enrollment of the Phase 2 Avail trial investigating canvuparatide for the treatment of hypoparathyroidism, we look forward to reporting top line results in the third quarter of 2025. We're also on track to submit our investigational new drug  application this quarter for MBX 4291, a novel glucagon-like peptide 1 /glucose-dependent insulinotropic polypeptide  co-agonist prodrug for treating obesity. In addition to these mileston","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4092","TM","BK4555","03160","PBH","BK4007","MBX","BK4604","BK4099","BK4585","HP"],"gpt_icon":0},{"id":"2533845631","title":"Microbix Biosystems to Release Q2 Fiscal 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2533845631","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533845631?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:58","pubTimestamp":1746705496,"startTime":"0","endTime":"0","summary":"Microbix Biosystms ( ($TSE:MBX) ) just unveiled an update. Microbix Biosystems Inc. has announced the release of its second quarter fiscal 2025 fin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-biosystems-to-release-q2-fiscal-2025-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-biosystems-to-release-q2-fiscal-2025-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2533865775","title":"Microbix Advances Kinlytic Urokinase Production with New CDMO Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2533865775","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533865775?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446431,"startTime":"0","endTime":"0","summary":"Microbix Biosystms ( ($TSE:MBX) ) has shared an update. Microbix Biosystems Inc. announced that its partner, Sequel Pharma, has signed an agreement...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-advances-kinlytic-urokinase-production-with-new-cdmo-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-advances-kinlytic-urokinase-production-with-new-cdmo-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CDMO","BK4007","BK4139","MBX"],"gpt_icon":0},{"id":"2531305750","title":"Kaia Network Users Reach Record High, as KLEVA Soars 119% | Top Altcoins to Watch Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2531305750","media":"BE[IN]CRYPTO","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531305750?lang=en_us&edition=fundamental","pubTime":"2025-04-29 23:30","pubTimestamp":1745940600,"startTime":"0","endTime":"0","summary":"Kleva  surged 119% recently but faces volatility; holding above $0.081 support could signal a potential recovery toward $0.092.Marblex  has risen 15% in 10 days, targeting $0.21 resistance; failure to hold $0.189 support could shift sentiment to bearish.Altcoins continue to shine not just on the top blockchains in the crypto space but even on the ones that are less well-known. One such is the Kaia network, which was noted to have a massive surge in users in April.According to the data on Dune, the total monthly active users peaked at 22.63 million in April, with the addition of 8 million users. BeInCrypto has analyzed three of the top-performing altcoins on the Kaia Network for investors to watch heading into May.However, if GRND fails to hold above the $0.0568 support level, the bullish outlook could be at risk. A drop below this level would likely lead to a decline toward $0.0494, wiping out a significant portion of the recent gains. This would invalidate the current bullish thesis a","market":"us","thumbnail":"https://beincrypto.com/wp-content/uploads/2024/10/bic_generic_memecoins_5-covers_bearish-850x478.jpg.optimal.jpg","type":0,"news_type":0,"thumbnails":["https://beincrypto.com/wp-content/uploads/2024/10/bic_generic_memecoins_5-covers_bearish-850x478.jpg.optimal.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://beincrypto.com/meme-coins-to-watch-today-kleva-grnd-mbx/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"beincrypto_highlight","symbols":["BK4007","KAIA.USD.HKCC","MBX","BK4077","FDV","GRND"],"gpt_icon":0},{"id":"2526571956","title":"My Foodie Box Explores New Ventures Post-Divestment","url":"https://stock-news.laohu8.com/highlight/detail?id=2526571956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526571956?lang=en_us&edition=fundamental","pubTime":"2025-04-11 10:08","pubTimestamp":1744337282,"startTime":"0","endTime":"0","summary":"My Foodie Box Limited ( ($AU:MBX) ) has shared an announcement. My Foodie Box Limited has completed the divestment of its meal kit business and is ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/my-foodie-box-explores-new-ventures-post-divestment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/my-foodie-box-explores-new-ventures-post-divestment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU0106261612.USD","LU0012050646.USD","BK4212","LU0240878834.USD","POST","MBX","BOX","BK4023","LU0240877869.USD"],"gpt_icon":0},{"id":"2526150571","title":"Director Makes Bold Move with Major MBX Biosciences Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2526150571","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526150571?lang=en_us&edition=fundamental","pubTime":"2025-04-11 10:02","pubTimestamp":1744336933,"startTime":"0","endTime":"0","summary":"New insider activity at MBX Biosciences, Inc. ( ($MBX) ) has taken place on April 11, 2025. Director Ora Pescovitz has made a significant investmen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-mbx-biosciences-stock-purchase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-mbx-biosciences-stock-purchase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2526505875","title":"Strategic Positioning and Market Dynamics Justify Buy Rating for Microbix Biosystems","url":"https://stock-news.laohu8.com/highlight/detail?id=2526505875","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526505875?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:25","pubTimestamp":1744284324,"startTime":"0","endTime":"0","summary":"Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Microbix Biosystms (MBX – Research Report), reducing the price target to C$0.80...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-positioning-and-market-dynamics-justify-buy-rating-for-microbix-biosystems?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-positioning-and-market-dynamics-justify-buy-rating-for-microbix-biosystems?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2525689592","title":"Microbix Biosystems Navigates Tariff Challenges with Strategic Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2525689592","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525689592?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:38","pubTimestamp":1744112310,"startTime":"0","endTime":"0","summary":"Microbix Biosystms ( ($TSE:MBX) ) has provided an announcement. Microbix Biosystems Inc. announced that its products remain exempt from new U.S. ta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-biosystems-navigates-tariff-challenges-with-strategic-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-biosystems-navigates-tariff-challenges-with-strategic-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2525012717","title":"Press Release: MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2525012717","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525012717?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:00","pubTimestamp":1744027200,"startTime":"0","endTime":"0","summary":"Hoerter brings decades of pharmaceutical commercialization, leadership, and board experience to help guide MBX's next phase of growth. CARMEL, Ind., April 07, 2025  -- MBX Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company's Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track record of building and growing life science companies.\"I am thrilled to welcome Steve Hoerter to the Company's Board as an independent director,\" said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. \"As a seasoned leader within the biopharmaceutical industry, Steve has scaled multiple biotech companies into revenue-generating commercial enterprises. We lo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX","BK4588","PBH","BK4092","TM","03160","HP","BK4604","BK4099","BK4555","BK4585"],"gpt_icon":0},{"id":"2520676137","title":"MBX Biosciences, Inc.: Promising Outlook with Strong Financials and Key Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2520676137","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520676137?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:26","pubTimestamp":1742300802,"startTime":"0","endTime":"0","summary":"Jefferies analyst Michael Yee maintained a Buy rating on MBX Biosciences, Inc. (MBX – Research Report) yesterday and set a price target of $35.00. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/mbx-biosciences-inc-promising-outlook-with-strong-financials-and-key-catalysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/mbx-biosciences-inc-promising-outlook-with-strong-financials-and-key-catalysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2520407555","title":"MBX Biosciences Q4 2024 GAAP EPS $(0.47) Beats $(0.59) Estimate, $262.1M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2024; Expected To Support Operations Into Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2520407555","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520407555?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:13","pubTimestamp":1742213603,"startTime":"0","endTime":"0","summary":"MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.59) by 20.34 percent. This is a 93.93 percent increase over losses of $(7.74) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44354431/mbx-biosciences-q4-2024-gaap-eps-0-47-beats-0-59-estimate-262-1m-in-cash-cash-equivalents-and-marke","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"MBX Biosciences Q4 2024 GAAP EPS $(0.47) Beats $(0.59) Estimate, $262.1M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2024; Expected To Support Operations Into Mid-2027","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"gpt_icon":0},{"id":"2520540896","title":"Mbx Biosciences Inc: Qtrly Loss per Share $0.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2520540896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520540896?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:03","pubTimestamp":1742212999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nFWN3Q00PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2520540983","title":"MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2520540983","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520540983?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:00","pubTimestamp":1742212800,"startTime":"0","endTime":"0","summary":"Enrollment complete in Phase 2 Avail trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025 MBX 1416 Phase 2 trial in patients with post-bariatric hypoglycemia expected to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/17/3043631/0/en/MBX-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX","PBH","BK4092","HP","PTH"],"gpt_icon":0},{"id":"2520676540","title":"Microbix Partners with ACPCC to Combat Cervical Cancer in Indo-Pacific","url":"https://stock-news.laohu8.com/highlight/detail?id=2520676540","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520676540?lang=en_us&edition=fundamental","pubTime":"2025-03-17 19:53","pubTimestamp":1742212424,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Microbix Biosystms ( ($TSE:MBX) ). Microbix Biosystems Inc. has signed a Memorandum of Understanding with the A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-partners-with-acpcc-to-combat-cervical-cancer-in-indo-pacific?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-partners-with-acpcc-to-combat-cervical-cancer-in-indo-pacific?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2519839578","title":"Insider Buyers At MBX Biosciences Likely Disappointed With 17% Slide","url":"https://stock-news.laohu8.com/highlight/detail?id=2519839578","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519839578?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:08","pubTimestamp":1741864125,"startTime":"0","endTime":"0","summary":"The recent price decline of 17% in MBX Biosciences, Inc.'s  stock may have disappointed insiders who bought US$534.5k worth of shares at an average price of US$10.69 in the past 12 months. Insiders purchase with the hope of seeing their investments increase in value over time. However, due to recent losses, their initial investment is now only worth US$469.5k, which is not great.While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-buyers-mbx-biosciences-likely-110845338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MBX","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":53,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"MBX","fiscalQuarterEnding":"2025/03","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.71},{"market":"US","date":"2025-03-17","symbol":"MBX","fiscalQuarterEnding":"2024/12","expectedEps":-0.59,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"pre","actualEps":-0.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MBX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1744344000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MBX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MBX","date":"2025-06-06","current":-5.395944,"percent":0.793478,"low":-18.37518,"twenty":-14.885451,"median":-6.813207,"eighty":-5.315894,"high":-3.125337,"avg":-9.285014,"sd":4.569883,"marketCap":396413040},"quantilePoints":[{"date":"2024-09-13","current":-15.960592,"twenty":-13.895501,"median":-10.797864,"eighty":-10.797864,"marketCap":753339957},{"date":"2024-09-20","current":-15.949203,"twenty":-15.694582,"median":-15.111074,"eighty":-12.419885,"marketCap":752802389},{"date":"2024-09-27","current":-16.939398,"twenty":-16.33255,"median":-15.751164,"eighty":-14.917986,"marketCap":799539567},{"date":"2024-10-04","current":-16.797941,"twenty":-16.986079,"median":-16.110499,"eighty":-15.091977,"marketCap":792862827},{"date":"2024-10-11","current":-16.932325,"twenty":-16.986079,"median":-16.31699,"eighty":-15.248994,"marketCap":799205730},{"date":"2024-10-18","current":-17.024271,"twenty":-17.032759,"median":-16.518565,"eighty":-15.369232,"marketCap":803545610},{"date":"2024-10-25","current":-15.022664,"twenty":-17.021442,"median":-16.380645,"eighty":-15.369232,"marketCap":709069745},{"date":"2024-11-01","current":-15.885548,"twenty":-16.991737,"median":-16.362963,"eighty":-15.369232,"marketCap":749797857},{"date":"2024-11-08","current":-13.874718,"twenty":-16.947885,"median":-16.309917,"eighty":-15.248994,"marketCap":765593046},{"date":"2024-11-15","current":-10.66494,"twenty":-16.936569,"median":-16.143706,"eighty":-14.480386,"marketCap":588480730},{"date":"2024-11-22","current":-11.203941,"twenty":-16.918179,"median":-15.949203,"eighty":-13.805677,"marketCap":618222233},{"date":"2024-11-29","current":-12.318278,"twenty":-16.877157,"median":-15.751164,"eighty":-12.380051,"marketCap":679710282},{"date":"2024-12-06","current":-13.432616,"twenty":-16.771064,"median":-15.461179,"eighty":-11.837418,"marketCap":741198331},{"date":"2024-12-13","current":-11.470413,"twenty":-16.663558,"median":-15.31265,"eighty":-11.837418,"marketCap":632925896},{"date":"2024-12-20","current":-12.330391,"twenty":-16.662143,"median":-15.019127,"eighty":-11.803503,"marketCap":680378630},{"date":"2024-12-27","current":-12.154761,"twenty":-16.656485,"median":-14.542475,"eighty":-11.803503,"marketCap":670687579},{"date":"2025-01-03","current":-11.258446,"twenty":-16.435813,"median":-14.054537,"eighty":-11.676323,"marketCap":621229800},{"date":"2025-01-10","current":-8.290916,"twenty":-16.380645,"median":-13.850493,"eighty":-11.492215,"marketCap":457484452},{"date":"2025-01-17","current":-5.989566,"twenty":-16.372157,"median":-13.75965,"eighty":-11.117943,"marketCap":330498264},{"date":"2025-01-24","current":-6.510398,"twenty":-16.36367,"median":-13.256987,"eighty":-10.797864,"marketCap":359237243},{"date":"2025-01-31","current":-6.06224,"twenty":-16.342452,"median":-12.878476,"eighty":-9.893382,"marketCap":334508354},{"date":"2025-02-07","current":-7.473331,"twenty":-16.314161,"median":-12.457571,"eighty":-8.809325,"marketCap":412370938},{"date":"2025-02-14","current":-6.304488,"twenty":-16.290113,"median":-12.324334,"eighty":-7.444262,"marketCap":347875321},{"date":"2025-02-21","current":-6.589128,"twenty":-16.247676,"median":-12.215323,"eighty":-7.171733,"marketCap":363581507},{"date":"2025-02-28","current":-5.813937,"twenty":-16.175534,"median":-12.009413,"eighty":-6.798672,"marketCap":320807212},{"date":"2025-03-07","current":-5.989566,"twenty":-16.064646,"median":-11.803503,"eighty":-6.591551,"marketCap":330498264},{"date":"2025-03-14","current":-5.26888,"twenty":-15.958314,"median":-11.682379,"eighty":-6.514032,"marketCap":290731536},{"date":"2025-03-21","current":-4.258879,"twenty":-15.936472,"median":-11.549143,"eighty":-6.294798,"marketCap":263718287},{"date":"2025-03-28","current":-4.188707,"twenty":-15.858671,"median":-11.258446,"eighty":-6.213645,"marketCap":259373118},{"date":"2025-04-04","current":-3.260282,"twenty":-15.749749,"median":-11.107042,"eighty":-6.057395,"marketCap":201883200},{"date":"2025-04-11","current":-3.999783,"twenty":-15.687509,"median":-10.797864,"eighty":-5.922948,"marketCap":247674589},{"date":"2025-04-17","current":-4.113138,"twenty":-15.461179,"median":-10.66494,"eighty":-5.686757,"marketCap":254693707},{"date":"2025-04-25","current":-4.949799,"twenty":-15.461179,"median":-9.901861,"eighty":-5.438453,"marketCap":306501482},{"date":"2025-05-02","current":-6.477382,"twenty":-15.454106,"median":-9.653557,"eighty":-5.327647,"marketCap":401092452},{"date":"2025-05-09","current":-5.996976,"twenty":-15.31265,"median":-8.539219,"eighty":-5.438453,"marketCap":371344761},{"date":"2025-05-16","current":-5.077465,"twenty":-15.206557,"median":-7.473331,"eighty":-5.077465,"marketCap":373015980},{"date":"2025-05-23","current":-5.691675,"twenty":-15.022664,"median":-7.246225,"eighty":-5.226487,"marketCap":418138881},{"date":"2025-05-30","current":-5.787218,"twenty":-15.017006,"median":-7.134185,"eighty":-5.260401,"marketCap":425157999},{"date":"2025-06-06","current":-5.395944,"twenty":-14.885451,"median":-6.813207,"eighty":-5.315894,"marketCap":396413040}],"updateTime":1749361850187}}}